Successful Toxicology Studies Accelerate Cytogenix Product Development.Business Editors/Health & Medical Writers HOUSTON--(BUSINESS WIRE)--Oct. 17, 2001 CytoGenix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announced that, as expected, the tests at Stillmeadow Inc. on its proprietary intracellular single stranded DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. expression system indicated no dermal toxicity dermal toxicity, n an adverse skin reaction to the application of essential oils and other substances; includes irritation, (inflammation, itching) sensitization (reactions occurring after initial contact), and phototoxicity, (increased vulnerability to sun). for topical application. Successful Toxicology results are the necessary first step toward preclinical and clinical trials. Dr. Malcolm Skolnick, CytoGenix CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , reports, "The successful results of our initial toxicology studies for topical applications of our technology for various dermatological conditions is a positive step in our path toward regulatory approval of products for sale in the US market. These results also boost our efforts to negotiate agreements for marketing our products outside the United States." Director of Research for the CytoGenix, Yin Chen, PhD, explains, "Acute dermal toxicity test of our company's ssDNA expression system in rats shows no clinical signs of toxicity at any time throughout the study. We are very pleased with the results. We can now move forward to test the efficacy of our single stranded DNA expression system by programming the plasmid to express various genes involved in topical applications. Our CYGXesT technology offers a unique approach to compete in the multi-billion dollar markets for the treatment of dermatological diseases such as alopecia alopecia (ăl'əpē`shēə): see baldness. , psoriasis, herpes, melanoma, and shingles shingles: see herpes zoster. shingles or herpes zoster Acute viral skin and nerve infection. Groups of small blisters appear along certain nerve segments, most often on the back, sometimes after a dull ache at the site; pain becomes among others." Topical skin products are the first in line for development and production because of the ease of applications and the size of the market. The skin is, after all, the largest organ in the human body and subject to the greatest exposure to disease and damage. The CytoGenix proprietary ssDNA expression systems have been demonstrated in independent research laboratories to be the most efficient means of producing effective intracellular levels of the ssDNA molecules useful in Oligonucleotide Mediated Intervention (OMI (1) See Open Market. (2) (Open Microprocessor Initiative, Brussels, Belgium) An organization that functions under the umbrella of the European Commission. It funds projects that research and develop advanced microcontroller technologies. ) therapies. OMI therapies are effective at the cellular level to block the production of harmful proteins caused by viruses, bacteria or other genomic pathologies using mechanisms of action that are very specific against only the targeted protein. The result is the prevention of disease-causing activities without introducing chemicals or foreign materials with possible toxic effects. The company is now marketing their single plasmid expression system (CYGXes1.1T) to research institutions and biotechs as a laboratory "tool kit." The CYGX expression systems enable superior intracellular production of the various gene sequences of interest. It is expected that successful results of the kit use in laboratories will lead to the licensing of the company's technology by biotechs and pharmaceutical companies for the successful development of literally thousands of revolutionary pharmacogenomic products. Cooperative Research and Development Agreements (CRADAs) are underway to combine the CytoGenix expression systems with delivery and uptake technology to more effectively target specific cell types in other organs and parts of the body. Stillmeadow Inc., established in 1975, is an independent contract research facility headquartered in Sugar Land, Texas. It offers services in the areas of toxicology (mammalian and aquatic), animal health (pet products, farm animals), analytical services (product chemistry and environmental fate), environmental services, biocompatability and in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. studies. Stillmeadow was accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC AAALAC Association for Assessment and Accreditation of Laboratory Animal Care (formerly American Association for the Accreditation of Laboratory Animal Care) International) in 1980, and has maintained that accreditation to date. SAFE HARBOR Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion